Aerocrine prevails in patent infringement suit against Medisoft

Aerocrine prevails in patent infringement suit against Medisoft

SOLNA, Sweden - 25 February 2011 - Aerocrine AB today announced the
positive outcome of its patent proceedings against Medisoft P.A.E. at
the Court of Appeal of Dusseldorf and the Federal Patent Court of
Munich.

In March 2008, Aerocrine sued the Belgian company Medisoft for patent
infringement before the District Court of Düsseldorf.  In September of
2009, the District Court announced its decisions that the Medisoft
device Hyp'Air FeNO infringes the German counterparts of Aerocrine's
patents EP 0 606 351 B1, EP 1 439 781 B1 and EP 0 724 723 B1.  These
European patents also cover Belgium, Switzerland, Spain, France, United
Kingdom, Ireland, Italy, Netherlands and Sweden.  The judgments were
subsequently appealed by Medisoft and Medisoft also filed nullity
proceedings against the three Aerocrine patents in Germany.

On February 1st 2011, the validity of Aerocrine's EP 0 724 723 B1 patent
was examined at a hearing at the Federal Patent Court in Munich.  The
patent was upheld following a change of the infringed patent claim.  An
additional patent claim in the EP 0 724 723 B1 patent, that was removed
from the original District Court procedure in 2009 pending a decision
regarding the patentability of this claim, was upheld by the Federal
Patent Court with a similar change of this claim.  The nullity cases on
the remaining two Aerocrine patents remain pending before the Munich
Court.

Yesterday, following a hearing on January 27th 2011, the Court of Appeal
in Dusseldorf confirmed the decisions by the District Court in 2009 that
the Medisoft device Hyp'Air FeNO infringes Aerocrine's patents EP 0 606
351 B1 and EP 1 439 781 B1.  The Court of Appeal will also revisit
Medisoft's appeal of the infringement of Aerocrine's EP 0 724 723 B1
patent following the positive decision by the Federal Patent Court, as
well as decide on Medisoft's alleged infringement of the additional
claim in the same patent.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80